Technical Analysis for LIPO - Lipella Pharmaceuticals Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | -4.00% | |
| Crossed Above 50 DMA | Bullish | -4.00% | |
| MACD Bullish Signal Line Cross | Bullish | -4.00% | |
| 180 Bullish Setup | Bullish Swing Setup | -4.00% | |
| Above Upper BB | Strength | -4.00% | |
| Gapped Up | Strength | -4.00% | |
| Up 3 Days in a Row | Strength | -4.00% | |
| Upper Bollinger Band Touch | Strength | -4.00% | |
| 20 DMA Resistance | Bearish | 3.78% | |
| 180 Bearish Setup | Bearish Swing Setup | 3.78% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 10 DMA Support | 26 minutes ago |
| Down 5% | about 3 hours ago |
| Down 3% | about 3 hours ago |
| Fell Below 50 DMA | about 3 hours ago |
| Down 2 % | about 3 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: Unknown
Lipella is a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. We believe that this strategy combines many of the cost efficiencies and risk abatements derived from using existing generic drugs with potential patent protections for our proprietary formulations; this strategy allows us to expedite, protect, and monetize our product candidates. Additionally, we maintain a therapeutic focus on diseases with significant, unaddressed morbidity and mortality where no approved drug therapy currently exists, believing that this focus can potentially help reduce the cost, time and risk associated with obtaining marketing approval.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Disease Generic Drug Drug Therapy
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Disease Generic Drug Drug Therapy
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 7.72 |
| 52 Week Low | 1.69 |
| Average Volume | 45,752 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 1.94 |
| 20-Day Moving Average | 1.88 |
| 10-Day Moving Average | 1.89 |
| Average True Range | 0.15 |
| RSI (14) | 54.75 |
| ADX | 9.28 |
| +DI | 19.68 |
| -DI | 15.80 |
| Chandelier Exit (Long, 3 ATRs) | 1.83 |
| Chandelier Exit (Short, 3 ATRs) | 2.15 |
| Upper Bollinger Bands | 1.98 |
| Lower Bollinger Band | 1.78 |
| Percent B (%b) | 1.09 |
| BandWidth | 10.92 |
| MACD Line | -0.02 |
| MACD Signal Line | -0.03 |
| MACD Histogram | 0.0094 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.19 | ||||
| Resistance 3 (R3) | 2.17 | 2.09 | 2.16 | ||
| Resistance 2 (R2) | 2.09 | 2.04 | 2.10 | 2.15 | |
| Resistance 1 (R1) | 2.04 | 2.01 | 2.06 | 2.06 | 2.14 |
| Pivot Point | 1.96 | 1.96 | 1.97 | 1.97 | 1.96 |
| Support 1 (S1) | 1.91 | 1.91 | 1.94 | 1.94 | 1.86 |
| Support 2 (S2) | 1.83 | 1.88 | 1.84 | 1.85 | |
| Support 3 (S3) | 1.78 | 1.83 | 1.84 | ||
| Support 4 (S4) | 1.81 |
